Pramipexole dihydrochloride


CAS No. : 104632-25-9

Pramipexole dihydrochloride,104632-25-9
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000256
Synonyms:(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;dihydrochloride
Molecular Formula:C10H17N3S • 2HCl
Molecular Weight:284.2
Target:Dopamine Receptor
IC50:3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4)
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance: Powder
Purity: 98.0%
Cat No:I000256
Cas No:104632-25-9
Product-Name:Pramipexole dihydrochloride
InChIKey:QMNWXHSYPXQFSK-KLXURFKVSA-N

Pramipexole 2Hcl is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively.
IC50 Value: 3.9 nM(D2S); 2.2 nM(D2L); 0.5 nM(D3); 5.1 nM(D4)
Target: Dopamine Receptor
Pramipexole dihydrochloride is a dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 3.9, 3.3, 0.5 and 3.9 nM for D2L, D2S, D3 and D4 receptors respectively). Pramipexole dihydrochloride exhibits negligable affinity for D1 and D5 receptors. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways. Pramipexole displays activity in the treatment of Parkinson/'s disease (PD) and restless legs syndrome (RLS).


[1]. Mierau J, Schneider FJ, Ensinger HA et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29-36.
[2]. El-Mallakh RS, Penagaluri P, Kantamneni A et al. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010 Sep;81(3):207-13.
[3]. Perez-Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson/'s disease. Expert Rev Neurother. 2011 Jul;11(7):925-35.
[4]. Hametner EM, Seppi K, Poewe W. Pramipexole extended release in Parkinson/'s disease. Expert Rev Neurother. 2011 Sep;11(9):1229-34.
[5]. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson/'s disease. Clin Interv Aging. 2012;7:83-8.

Related Products
  • CAS No. :76135-30-3
    Product Name:

    7-Hydroxy-DPAT hydrobromide

    Cat No: I010283 View details
  • CAS No. :62-31-7
    Product Name:

    Dopamine HCl

    Cat No: A000771 View details
  • CAS No. :108179-91-5
    Product Name:

    SKF 83566 Hydrobromide

    Cat No: R028244 View details
  • CAS No. :101626-70-4
    Product Name:

    Talipexole

    Cat No: I000130 View details